Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S V Otton

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Journal of Clinical Psychopharmacology|August 1, 1995
Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibitionM Schadel, D Wu, S V Otton, et al.
Drug and Alcohol Dependence|June 18, 1999
Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeysS Lelas, S Wegert, S V Otton, et al.
Journal of Clinical Psychopharmacology|February 1, 2000
Cytochrome P450 2D6 and treatment of codeine dependenceM K Romach, S V Otton, G Somer, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1993
Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitroD Wu, S V Otton, P Morrow, et al.
Biochemical Pharmacology|July 25, 1991
Assessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine typeM Adams, M S Lennard, S V Otton, et al.
European Journal of Clinical Pharmacology|January 1, 1986
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphismK Brøsen, R Klysner, L F Gram, et al.
Clinical Pharmacology and Therapeutics|April 1, 1993
Inhibition by fluoxetine of cytochrome P450 2D6 activityS V Otton, D Wu, R T Joffe, et al.
Biochemical Pharmacology|April 15, 1991
Characterization of metronidazole metabolism by human liver microsomesS Loft, S V Otton, M S Lennard, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1988
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomesS V Otton, H K Crewe, M S Lennard, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 1, 1992
Catalytic and immunologic similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6)S V Otton, R F Tyndale, D Wu, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Journal of Clinical Psychopharmacology|August 1, 1995
Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibitionM Schadel, D Wu, S V Otton, et al.
Drug and Alcohol Dependence|June 18, 1999
Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeysS Lelas, S Wegert, S V Otton, et al.
Journal of Clinical Psychopharmacology|February 1, 2000
Cytochrome P450 2D6 and treatment of codeine dependenceM K Romach, S V Otton, G Somer, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1993
Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitroD Wu, S V Otton, P Morrow, et al.
Biochemical Pharmacology|July 25, 1991
Assessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine typeM Adams, M S Lennard, S V Otton, et al.
European Journal of Clinical Pharmacology|January 1, 1986
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphismK Brøsen, R Klysner, L F Gram, et al.
Clinical Pharmacology and Therapeutics|April 1, 1993
Inhibition by fluoxetine of cytochrome P450 2D6 activityS V Otton, D Wu, R T Joffe, et al.
Biochemical Pharmacology|April 15, 1991
Characterization of metronidazole metabolism by human liver microsomesS Loft, S V Otton, M S Lennard, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1988
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomesS V Otton, H K Crewe, M S Lennard, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 1, 1992
Catalytic and immunologic similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6)S V Otton, R F Tyndale, D Wu, et al.
Pageof 4